{"name":"CorMedix","slug":"cormedix","ticker":"CRMD","exchange":"NASDAQ","domain":"cormedix.com","description":"CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New Jersey.","hq":"Berkeley Heights, NJ","founded":0,"employees":"191","ceo":"Joe Todisco","sector":"Anti-Infective / Specialty Pharma","stockPrice":8.11,"stockChange":0.61,"stockChangePercent":8.13,"marketCap":"$636M","metrics":{"revenue":311709000,"revenueGrowth":312.1,"grossMargin":92.9,"rdSpend":19333000,"netIncome":163055000,"cash":148531008,"dividendYield":0,"peRatio":4,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Taurolidine patent cliff ($0.0B at risk)","drug":"Taurolidine","type":"patent_expiry","sentiment":"negative"},{"date":"2030-06-01","label":"Heparin patent cliff ($0.0B at risk)","drug":"Heparin","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"CRMD-001-Deferiprone","genericName":"CRMD-001-Deferiprone","slug":"crmd-001-deferiprone","indication":"Beta-thalassemia major","status":"phase_2"},{"name":"Taurolidine and Heparin","genericName":"Taurolidine and Heparin","slug":"taurolidine-and-heparin","indication":"Hematology","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Neutrolin","genericName":"Neutrolin","slug":"neutrolin","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"CRMD-001-Deferiprone","genericName":"CRMD-001-Deferiprone","slug":"crmd-001-deferiprone","phase":"phase_2","mechanism":"Iron chelator","indications":["Beta-thalassemia major","Sickle cell disease"],"catalyst":""},{"name":"Neutrolin","genericName":"Neutrolin","slug":"neutrolin","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Taurolidine and Heparin","genericName":"Taurolidine and Heparin","slug":"taurolidine-and-heparin","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"CorMedix Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"CorMedix reported its financial results for the fourth quarter and full year 2023, highlighting revenue growth and a strong pipeline of products.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"deal","headline":"CorMedix Announces Exclusive Distribution Agreement for Neutrolin in the United States","summary":"CorMedix entered into an exclusive distribution agreement with a leading healthcare company for Neutrolin in the United States.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-19","type":"pipeline","source":"simplywall.st","summary":"Is CorMedix (CRMD) Now Offering Value After Sharp Share Price Declines? - simplywall.st","headline":"Is CorMedix (CRMD) Now Offering Value After Sharp Share Price Declines?","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-17","type":"pipeline","source":"simplywall.st","summary":"Assessing CorMedix (CRMD) Valuation After Recent Share Price Weakness And Long Term Gains - simplywall.st","headline":"Assessing CorMedix (CRMD) Valuation After Recent Share Price Weakness And Long Term Gains","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-08","type":"earnings","source":"simplywall.st","summary":"CorMedix (CRMD) Is Down 9.4% After Reaffirming 2026 Guidance and Reporting Profit Swing - What's Changed - simplywall.st","headline":"CorMedix (CRMD) Is Down 9.4% After Reaffirming 2026 Guidance and Reporting Profit Swing - What's Changed","sentiment":"neutral"},{"date":"2026-03-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"date":"2026-03-05","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: ANNUAL REPORT","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPanc0cEJTWFV1MGdVY3laeUNDb3h6UHktWk1tQmJ6eTlYb3pMRDI5TVZOVnBYSFh5RHVWcUJjVnVPU3owQUlmYzY1T2w0V3VXNUdYaHc1TFluN055N2FwM0lWWGluSGhrTnd1RDJubHFLVWhoRlg4T0FzQ1RUSWVHcUpqMExhSGVhcUpOVlRNOG16WnFLenlUam5kdlk?oc=5","date":"2026-02-23","type":"earnings","source":"Finviz","summary":"Should Investors Buy, Sell or Hold CRMD Stock Ahead of Q4 Earnings? - Finviz","headline":"Should Investors Buy, Sell or Hold CRMD Stock Ahead of Q4 Earnings?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxQUFplZ1ljT1A4X0h0UHdsMUJuVk16VV9OcDNnWF9ydWE0ekl2VFN5UjZHamJLQUhBaUpBQzZqenN0ZjEzRFZfNUJhd29JZGliTTZrSDJTS0tCMFVrMEYwMks3V1dnMGlYLWRrLWdYMEllZTJ4b3JSczNnVmthMHM2MEhibWRHdnNpUExGQWY3dC1LdHJYWFhGMm9vSklncGR4LXBNNzVFUG5WUHpiMEc5ZnFEMA?oc=5","date":"2026-02-17","type":"pipeline","source":"TradingView","summary":"CorMedix Down 27% in 3 Months: Is It Time to Sell the Stock? - TradingView","headline":"CorMedix Down 27% in 3 Months: Is It Time to Sell the Stock?","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-06","type":"pipeline","source":"simplywall.st","summary":"CorMedix Inc. (NASDAQ:CRMD) Not Doing Enough For Some Investors As Its Shares Slump 35% - simplywall.st","headline":"CorMedix Inc. (NASDAQ:CRMD) Not Doing Enough For Some Investors As Its Shares Slump 35%","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPSmV4akE3V3I4TUpNZDVaY0xFUUxVX2doQ1U0alNpVkQ5YmVVbkVhMW5sYWFfTzlPMEpwMDN5Zy1TeUtPVkV6TU1lLUV2SjhaVVdVTFFmemVxVE5ab2NMWk9SXy1iUXlRenhLcTJYUUdyczRWYjJJY1YxVjRJRUs5bG9ycHV2OGM2ZUdiUGZib0F6TzlVSjlrcUZR?oc=5","date":"2026-01-30","type":"pipeline","source":"Finviz","summary":"CRMD Down 31% in a Month: Is This an Indication to Sell the Stock? - Finviz","headline":"CRMD Down 31% in a Month: Is This an Indication to Sell the Stock?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxOc0k1SGZKTzBEWVgzZlEtQnFIdVZoY3lTQ1JiSHJsVWNuNmk3TjRJUnVCVnpwR0F2RjQxWS1sWlBPZzNab2prb0ZOaERsVGs0VG1vUEJhdmplMzl0dEZzR21zXzV2cXdsR2IxYk43RnFLeF85b2VZY1YyQzI0d0xPMw?oc=5","date":"2026-01-20","type":"deal","source":"Yahoo Finance","summary":"CorMedix vs. Mirum Pharma: Which Rare-Disease Stock is the Better Buy? - Yahoo Finance","headline":"CorMedix vs. Mirum Pharma: Which Rare-Disease Stock is the Better Buy?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNNHBUeHBua296dDc4VjVHUVIybUR4SzdKQ0tTUGkzU0hzcUVvRGlJS21xcTRmWllVN2NQLUM0aDk3bGtRVV9vUjZPemhvUF9zNVpoSjh5QjlQUEtoR2R2Ty1WV19wTlptVk1ITEhUV1ByNkNuODl0eHJsNDBUWDQ1S29GcjlGR3FQQktWcjdtc1AtQTFF?oc=5","date":"2025-12-11","type":"deal","source":"Finviz","summary":"CRMD Up More Than 40% YTD: Time to Buy, Sell or Hold the Stock? - Finviz","headline":"CRMD Up More Than 40% YTD: Time to Buy, Sell or Hold the Stock?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQU2V4NGxCYXJwSG9iSDBTeDhhX2RxeTFoS3JGcUhnd1Z4VWJqUUdhd1ZoUjdEODZCWTNtdnJoM01xMXduWXFqajBnSmJJVXVGUzJYSDJ4azdYOXhsUjFnRy05LTJ6UjE3bTh6Q3lBOGNPWm9jd1lMdTdld3V1RkU2LVJ5eVRWLXhLU1FPeVJTTldxN0ZWc01CNUhqVjhkSEVf?oc=5","date":"2025-07-30","type":"pipeline","source":"Markets.com","summary":"Biotech Stocks to Watch: EXEL Stock, CRMD Stock, HRMY Stock, ETON, ATRA - Markets.com","headline":"Biotech Stocks to Watch: EXEL Stock, CRMD Stock, HRMY Stock, ETON, ATRA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxNbUk1NU81blQzcW9sVlU4MUx6ZHBWSGswT205Q0YtbzJqUHJnTmdtaVFCLUJTNkFvRE00U3lvNGNmQnhsN2VTWklIWlAzSXQ3OUdxVDdtV21fdHh0WWNnU3F3b1lmbllORnR5T2pFTDZMY3lIWkFEMFl5X0VIeHhaOEswOVd1YXcz?oc=5","date":"2025-06-30","type":"pipeline","source":"Seeking Alpha","summary":"CorMedix Seems Significantly Undervalued (NASDAQ:CRMD) - Seeking Alpha","headline":"CorMedix Seems Significantly Undervalued (NASDAQ:CRMD)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTE9yNTNTZkZyaWtaeWF5T2xrZlRhUFBudmJ0ZzJuSGVsZENhUy1WajRsNjVwVnBQX3BBUFI0RDFndWN5VVRpaURLZE53b1c0UmZX?oc=5","date":"2024-02-12","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"}],"patents":[{"drugName":"Taurolidine","drugSlug":"taurolidine","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0},{"drugName":"Heparin","drugSlug":"heparin","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0}],"drugCount":3,"phaseCounts":{"phase_2":1,"phase_3":1,"marketed":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Spectrum Pharmaceuticals","AcelRx Pharmaceuticals","Takeda Pharmaceutical"],"therapeuticFocus":["Anti-Infective","Specialty Pharma"],"financials":{"source":"sec_edgar+yahoo","revenue":311709000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":311709000,"period":"2025-12-31"},{"value":43472170,"period":"2024-12-31"},{"value":43472000,"period":"2024-12-31"},{"value":65408,"period":"2022-12-31"},{"value":65408,"period":"2022-12-31"}],"grossProfit":275748000,"grossProfitHistory":[{"period":"2025-12-31","value":275748000},{"period":"2024-12-31","value":40282000},{"period":"2023-12-31","value":0},{"period":"2022-12-31","value":61674}],"rdSpend":19333000,"rdSpendHistory":[{"period":"2025-12-31","value":19333000},{"period":"2024-12-31","value":3942000},{"period":"2023-12-31","value":13155125},{"period":"2022-12-31","value":10679549}],"sgaSpend":106274000,"operatingIncome":150141000,"operatingIncomeHistory":[{"period":"2025-12-31","value":150141000},{"period":"2024-12-31","value":-22356000},{"period":"2023-12-31","value":-48957788},{"period":"2022-12-31","value":-30623968}],"netIncome":163055000,"netIncomeHistory":[{"period":"2025-12-31","value":163055000},{"period":"2024-12-31","value":-17930000},{"period":"2023-12-31","value":-46339227},{"period":"2022-12-31","value":-29701705}],"eps":2.04,"epsHistory":[{"period":"2025-12-31","value":2.04},{"period":"2024-12-31","value":-0.3},{"period":"2023-12-31","value":-0.91},{"period":"2022-12-31","value":-0.74}],"cash":144837000,"cashHistory":[{"period":"2025-12-31","value":144837000},{"period":"2024-12-31","value":40651000},{"period":"2023-12-31","value":43642684},{"period":"2022-12-31","value":43148323}],"totalAssets":826142000,"totalLiabilities":420835000,"totalDebt":148914000,"equity":405307000,"operatingCashflow":175046000,"operatingCashflowHistory":[{"period":"2025-12-31","value":175046000},{"period":"2024-12-31","value":-50615000},{"period":"2023-12-31","value":-38409480},{"period":"2022-12-31","value":-24356732}],"capex":-2260000,"capexHistory":[{"period":"2025-12-31","value":-2260000},{"period":"2024-12-31","value":-116000},{"period":"2023-12-31","value":-327300},{"period":"2022-12-31","value":-219360}],"freeCashflow":172786000,"dividendsPaid":null,"buybacks":null,"employees":191,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":39581587,"ebit":58263515,"ebitda":68697166,"period":"2025-12-31","revenue":128615264,"epsBasic":0.18,"netIncome":14020141,"rdExpense":8600207,"epsDiluted":0.16,"grossProfit":107308042,"operatingIncome":59126248},{"sga":36637063,"ebit":53524420,"ebitda":57314886,"period":"2025-09-30","revenue":104275289,"epsBasic":1.42,"netIncome":108562980,"rdExpense":5097644,"epsDiluted":1.26,"grossProfit":93080673,"operatingIncome":51345966},{"sga":15888128,"ebit":20356159,"ebitda":20519100,"period":"2025-06-30","revenue":39736790,"epsBasic":0.29,"netIncome":19827981,"rdExpense":2442709,"epsDiluted":0.28,"grossProfit":37874342,"operatingIncome":19543505},{"sga":14167222,"ebit":20653905,"ebitda":20815847,"period":"2025-03-31","revenue":39081657,"epsBasic":0.32,"netIncome":20643898,"rdExpense":3192440,"epsDiluted":0.3,"grossProfit":37484942,"operatingIncome":20125280},{"sga":15371650,"ebit":13474411,"ebitda":13608086,"period":"2024-12-31","revenue":31209936,"epsBasic":0.22,"netIncome":13464404,"rdExpense":1726719,"epsDiluted":0.22,"grossProfit":30034377,"operatingIncome":12936008}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":8.11,"previousClose":7.5,"fiftyTwoWeekHigh":17.43,"fiftyTwoWeekLow":6.13,"fiftyTwoWeekRange":"6.13 - 17.43","fiftyDayAverage":7.1,"twoHundredDayAverage":9.7,"beta":1.46,"enterpriseValue":593260992,"forwardPE":11.3,"priceToBook":1.58,"priceToSales":2.04,"enterpriseToRevenue":1.9,"enterpriseToEbitda":3.39,"pegRatio":0,"ebitda":174890000,"ebitdaMargin":56.1,"freeCashflow":108508376,"operatingCashflow":175046000,"totalDebt":148914000,"debtToEquity":36.7,"currentRatio":2.11,"returnOnAssets":21.2,"returnOnEquity":66.6,"analystRating":"1.4 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":7,"targetMeanPrice":15,"targetHighPrice":19,"targetLowPrice":13,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":7.5,"institutionHeldPercent":57,"sharesOutstanding":78442290,"floatShares":68044999,"sharesShort":16222947,"shortRatio":16.03,"shortPercentOfFloat":20.7,"epsTrailing":2.04,"epsForward":0.72,"revenuePerShare":4.33,"bookValue":5.11,"officers":[{"age":49,"name":"Mr. Joseph  Todisco MBA","title":"CEO & Chairman of the Board of Directors"},{"age":46,"name":"Ms. Elizabeth  Masson-Hurlburt B.A.","title":"Executive VP, Chief Operating Officer & Chief Integration Officer"},{"age":64,"name":"Ms. Kaufman Beth Zelnick Esq.","title":"EVP, Chief Legal and Compliance Officer & Corporate Secretary"},{"age":52,"name":"Ms. Susan  Blum","title":"EVP & Chief Financial Officer"},{"age":null,"name":"Ms. Beth  Steinbrenner","title":"SVP & Chief Human Resource Officer"},{"age":47,"name":"Dr. Matthew T. David M.D.","title":"EVP & Chief Business Officer"},{"age":null,"name":"Donna  Ucci","title":"Senior VP & Head of Global Quality"},{"age":null,"name":"Dr. Tushar  Mukherjee","title":"Senior VP & Head of Technical Operations"}],"industry":"Biotechnology","irWebsite":"","website":"https://cormedix.com","phone":"908 517 9500"}}